You are here


Sort By:

Hurov JB, Huang M, White LS, Lennerz J, Choi CSoo, Cho Y-R, Kim H-J, Prior JL, Piwnica-Worms D, Cantley LC et al..  2007.  Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo.. Proc Natl Acad Sci U S A. 104(13):5680-5.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JOh, Lindeman N, Gale C-M, Zhao X, Christensen J et al..  2007.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.. Science. 316(5827):1039-43.
Taniguchi CM, Alemán JO, Ueki K, Luo J, Asano T, Kaneto H, Stephanopoulos G, Cantley LC, C Kahn R.  2007.  The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance.. Mol Cell Biol. 27(8):2830-40.
Asara JM, Schweitzer MH, Freimark LM, Phillips M, Cantley LC.  2007.  Protein sequences from mastodon and Tyrannosaurus rex revealed by mass spectrometry.. Science. 316(5822):280-5.
Zheng B, Cantley LC.  2007.  Regulation of epithelial tight junction assembly and disassembly by AMP-activated protein kinase.. Proc Natl Acad Sci U S A. 104(3):819-22.
Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE et al..  2007.  T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling.. Blood. 109(7):2894-902.
Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale C-M, Naumov GN, Yeap BY, Jarrell E, Sun J et al..  2006.  Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.. J Clin Invest. 116(10):2695-706.
Schulze H, Korpal M, Hurov J, Kim S-W, Zhang J, Cantley LC, Graf T, Shivdasani RA.  2006.  Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis.. Blood. 107(10):3868-75.
Turk BE, Hutti JE, Cantley LC.  2006.  Determining protein kinase substrate specificity by parallel solution-phase assay of large numbers of peptide substrates.. Nat Protoc. 1(1):375-9.
Taniguchi CM, Kondo T, Sajan M, Luo J, Bronson R, Asano T, Farese R, Cantley LC, C Kahn R.  2006.  Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta.. Cell Metab. 3(5):343-53.
Engelman JA, Luo J, Cantley LC.  2006.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.. Nat Rev Genet. 7(8):606-19.
Weiner OD, Rentel MC, Ott A, Brown GE, Jedrychowski M, Yaffe MB, Gygi SP, Cantley LC, Bourne HR, Kirschner MW.  2006.  Hem-1 complexes are essential for Rac activation, actin polymerization, and myosin regulation during neutrophil chemotaxis.. PLoS Biol. 4(2):e38.
Asara JM, Zhang X, Zheng B, Maroney LA, Christofk HR, Wu N, Cantley LC.  2006.  In-gel stable isotope labeling for relative quantification using mass spectrometry.. Nat Protoc. 1(1):46-51.
Asara JM, Zhang X, Zheng B, Christofk HH, Wu N, Cantley LC.  2006.  In-Gel Stable-Isotope Labeling (ISIL): a strategy for mass spectrometry-based relative quantification.. J Proteome Res. 5(1):155-63.
Luo J, Sobkiw CL, Hirshman MF, M Logsdon N, Li TQ, Goodyear LJ, Cantley LC.  2006.  Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia.. Cell Metab. 3(5):355-66.
Turk BE, Lee DH, Yamakoshi Y, Klingenhoff A, Reichenberger E, J Wright T, Simmer JP, Komisarof JA, Cantley LC, Bartlett JD.  2006.  MMP-20 is predominately a tooth-specific enzyme with a deep catalytic pocket that hydrolyzes type V collagen.. Biochemistry. 45(12):3863-74.
Taniguchi CM, Tran TT, Kondo T, Luo J, Ueki K, Cantley LC, C Kahn R.  2006.  Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN.. Proc Natl Acad Sci U S A. 103(32):12093-7.
Shaw RJ, Cantley LC.  2006.  Ras, PI(3)K and mTOR signalling controls tumour cell growth.. Nature. 441(7092):424-30.
Engelman JA, Cantley LC.  2006.  The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors.. Clin Cancer Res. 12(14 Pt 2):4372s-4376s.
Oak JS, Deane JA, Kharas MG, Luo J, Lane TE, Cantley LC, Fruman DA.  2006.  Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase.. Proc Natl Acad Sci U S A. 103(45):16882-7.
Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS.  2005.  Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.. Cancer Res. 65(23):10992-1000.
Park J, Hu Y, Murthy TVS, Vannberg F, Shen B, Rolfs A, Hutti JE, Cantley LC, Labaer J, Harlow E et al..  2005.  Building a human kinase gene repository: bioinformatics, molecular cloning, and functional validation.. Proc Natl Acad Sci U S A. 102(23):8114-9.
Benes CH, Wu N, Elia AEH, Dharia T, Cantley LC, Soltoff SP.  2005.  The C2 domain of PKCdelta is a phosphotyrosine binding domain.. Cell. 121(2):271-80.
Luo J, McMullen JR, Sobkiw CL, Zhang L, Dorfman AL, Sherwood MC, M Logsdon N, Horner JW, DePinho RA, Izumo S et al..  2005.  Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy.. Mol Cell Biol. 25(21):9491-502.
Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC et al..  2005.  Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.. J Natl Cancer Inst. 97(16):1185-94.